```html

Aortitis: Comprehensive Medical Guide

Overview

Aortitis is an inflammation of the wall of the aorta, the largest artery in the body that carries oxygen‑rich blood from the heart to the rest of the organs and tissues. The inflammation can involve any segment of the aorta—ascending, arch, descending thoracic, or abdominal—but most commonly affects the thoracic portion.

Two major categories exist:

• Infectious aortitis – caused by bacteria, fungi, or mycobacteria.
• Non‑infectious (immune‑mediated) aortitis – often part of a systemic vasculitis such as Takayasu arteritis, giant cell arteritis, or Behçet’s disease.

The condition can affect adults of any age, but the epidemiology differs by type:

• Giant‑cell arteritis (GCA) – most common in people >50 years, especially women of Northern European descent; incidence ≈ 20‑30 cases per 100,000 persons per year (Mayo Clinic).
• Takayasu arteritis – typically presents in women <40 years, with an estimated prevalence of 1–3 per million worldwide (WHO).
• Infectious aortitis – rare, accounting for <1 % of all aortic aneurysms; incidence rises in immunocompromised individuals (CDC).

Although aortitis is uncommon overall, its potential for life‑threatening complications (e.g., aneurysm, dissection, rupture) makes early recognition essential.

Symptoms

Symptoms vary according to the extent of aortic involvement, the underlying cause, and whether complications have developed. Below is a complete list of commonly reported manifestations:

• Fever & chills – especially with infectious aortitis.
• Persistent, dull back or chest pain – may be described as a deep, aching discomfort that worsens with deep breathing or movement.
• Abdominal pain or fullness – more typical when the abdominal aorta is inflamed.
• Weight loss & fatigue – constitutional symptoms seen in immune‑mediated vasculitis.
• Headache, scalp tenderness, jaw claudication – hallmark signs of giant‑cell arteritis that can coexist with aortic inflammation.
• Upper extremity claudication, diminished pulses – seen in Takayasu arteritis when subclavian or carotid arteries are involved.
• Night sweats – may suggest an underlying infection.
• Low‑grade fever – frequent in chronic inflammatory forms.
• Neurologic symptoms – dizziness, syncope, or stroke‑like events when the aortic arch branches are compromised.
• Hypertension or new‑onset high blood pressure – can result from renal artery involvement.
• Pulsatile abdominal mass – sign of an expanding aneurysm, a late finding.

Because many of these signs overlap with other conditions, a high index of suspicion is required, especially in patients with known systemic vasculitis or persistent fever of unknown origin.

Causes and Risk Factors

Infectious Aortitis

• Bacterial pathogens – Salmonella spp., Staphylococcus aureus, Streptococcus pneumoniae, and less commonly Listeria.
• Fungal agents – Aspergillus, Candida (more common in immunosuppressed hosts).
• Mycobacterial infection – Mycobacterium tuberculosis can cause “tuberculous aortitis.”
• Risk factors – advanced age, atherosclerotic disease, prior vascular grafts or endografts, immunosuppression (e.g., chemotherapy, HIV), and intravenous drug use.

Non‑Infectious (Immune‑Mediated) Aortitis

• Giant‑cell arteritis (GCA) – autoimmune inflammation of medium‑ and large‑size arteries; predominates in individuals >50 y.
• Takayasu arteritis – T‑cell mediated granulomatous vasculitis; most common in Asian women <40 y.
• Other systemic vasculitides – Behçet’s disease, rheumatoid arthritis, systemic lupus erythematosus, and polyarteritis nodosa.
• Genetic predisposition – HLA‑DRB1*04 alleles linked with GCA; HLA‑B*52 associated with Takayasu (NIH).
• Environmental triggers – Chronic infections (e.g., CMV, EBV) may act as a “second hit” in genetically susceptible individuals.

General Risk Factors

• Older age (especially >50 y for GCA).
• Female sex – women are 2–3 times more likely to develop GCA and Takayasu.
• Smoking and uncontrolled hypertension – exacerbate atherosclerotic changes that can predispose to infectious aortitis.
• History of aortic surgery or endovascular procedures – provides a nidus for infection.

Diagnosis

Diagnosing aortitis requires an integration of clinical suspicion, laboratory testing, and imaging. No single test is definitive for all cases.

Laboratory Evaluation

• Inflammatory markers – Elevated erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) are present in >80 % of immune‑mediated aortitis (Cleveland Clinic).
• Complete blood count – May reveal anemia of chronic disease, leukocytosis (infectious), or eosinophilia (eosinophilic vasculitis).
• Blood cultures – Essential when infection is suspected; positivity in 30–50 % of bacterial aortitis.
• Serologic tests – Antineutrophil cytoplasmic antibodies (ANCA), antinuclear antibody (ANA), rheumatoid factor; help identify underlying systemic disease.

Imaging Studies

• Contrast‑enhanced CT angiography (CTA) – First‑line for most centers; shows wall thickening, periaortic edema, and aneurysm formation.
• Magnetic resonance angiography (MRA) – Useful in patients with renal insufficiency; provides excellent soft‑tissue contrast and can detect mural inflammation.
• 18F‑FDG PET/CT – Detects metabolic activity of inflamed aortic tissue; recommended when the diagnosis is unclear or to monitor treatment response (American College of Rheumatology).
• Transesophageal echocardiography (TEE) – Helpful for ascending aortic involvement and detecting aortic valve regurgitation.

Pathology (Rare)

In selected surgical cases, aortic tissue can be obtained for histopathology confirming granulomatous inflammation, giant cells, or microbial organisms. This is rarely needed because imaging plus clinical correlation yields a reliable diagnosis.

Diagnostic Criteria (Giant‑Cell Arteritis)

The 2022 American College of Rheumatology (ACR) criteria for GCA include:

1. Age ≥50 years.
2. New‑onset localized headache.
3. Temporal artery abnormality (tenderness or reduced pulse).
4. Elevated ESR ≥50 mm/h.
5. Biopsy showing necrotizing vasculitis with multinucleated giant cells.

Presence of ≥3 criteria gives a sensitivity of 93 % and specificity of 91 %.

Treatment Options

Therapy is tailored to the underlying cause, disease severity, and patient comorbidities.

Initial Stabilization

• IV fluids and analgesia for pain control.
• Broad‑spectrum antibiotics (e.g., ceftriaxone + vancomycin) if infectious aortitis is suspected, until cultures guide narrowing.
• Hemodynamic monitoring for signs of impending rupture or dissection.

Pharmacologic Management

Immune‑Mediated Aortitis

• Glucocorticoids – Prednisone 40‑60 mg/day (≈0.7 mg/kg) is first‑line for GCA and Takayasu. Taper slowly over months to minimize relapse.
• Steroid‑sparing agents – Methotrexate (15‑25 mg weekly) or azathioprine (2 mg/kg) can reduce cumulative steroid exposure.
• Biologic therapies –
  • Tocilizumab (IL‑6 receptor antagonist) 162 mg subcutaneously weekly has shown 55 % remission at 52 weeks in GCA (Mayo Clinic trial).
  • TNF‑α inhibitors (infliximab, adalimumab) have limited data but may help refractory Takayasu.

Infectious Aortitis

• Targeted antimicrobial therapy (e.g., 6–12 weeks of IV ceftriaxone for Salmonella aortitis) based on culture sensitivities.
• Adjunctive surgical or endovascular repair is often required when an aneurysm >5 cm, rapid expansion, or contained rupture is present.

Surgical & Endovascular Interventions

• Open surgical repair – Resection of the diseased segment with graft replacement; indicated for extensive infection or large aneurysms.
• Endovascular aneurysm repair (EVAR) – Less invasive; preferred in high‑risk surgical candidates, but infection must be controlled first.
• Bypass procedures – For critical limb ischemia due to arterial stenosis from Takayasu.

Lifestyle & Adjunctive Measures

• Blood pressure control (goal <130/80 mmHg) with ACE inhibitors or ARBs.
• Statin therapy for atherosclerotic risk reduction.
• Smoking cessation – decreases infection risk and atherosclerosis.
• Vaccinations (influenza, pneumococcal, COVID‑19) especially when on immunosuppressants.
• Regular physical activity as tolerated, focusing on low‑impact aerobic exercise.

Living with Aortitis

Chronic aortitis requires ongoing self‑management and regular medical follow‑up.

• Follow‑up imaging – CTA or MRA every 3–6 months initially, then annually if stable.
• Medication adherence – Never skip steroids or biologics without consulting a physician; abrupt withdrawal can precipitate flare.
• Monitor symptoms – Keep a diary of pain, fevers, or new neurologic changes and report promptly.
• Stress management – Chronic disease can impact mental health; consider counseling, mindfulness, or support groups.
• Travel considerations – Carry a letter summarizing diagnosis, current meds, and emergency contacts; ensure access to sterile water and safe food to limit infection risk.
• Bone health – Long‑term steroids increase osteoporosis risk; supplement calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day) and obtain a DEXA scan every 1–2 years.

Prevention

While aortitis itself cannot always be prevented, steps can reduce the likelihood of triggering events and complications.

• Control cardiovascular risk factors – blood pressure, cholesterol, diabetes, and smoking.
• Prompt treatment of bacterial infections, especially in older adults or those with vascular grafts.
• Vaccinate against influenza, pneumococcus, and COVID‑19 to lower systemic inflammatory burden.
• Maintain regular health screenings for systemic vasculitides if you have a family history or known autoimmune disease.
• Practice good hygiene and wound care, particularly after surgery or invasive procedures.

Complications

If left untreated or inadequately managed, aortitis can lead to serious, sometimes fatal outcomes:

• Aortic aneurysm formation – Occurs in up to 30 % of GCA patients within 5 years (NEJM).
• Aortic dissection – Tear in the aortic wall; mortality >50 % without emergent surgery.
• Rupture – Sudden intra‑abdominal or thoracic bleeding; immediate death in many cases.
• Arterial stenosis/occlusion – Can cause limb ischemia, renal failure, or cerebrovascular events.
• Heart‑valve involvement – Aortic regurgitation due to root dilation.
• Infection‑related sepsis – Particularly with bacterial aortitis.
• Medication side effects – Osteoporosis, diabetes, cataracts, and immunosuppression‑related infections from long‑term steroids.

When to Seek Emergency Care

If you experience any of the following, call 911 or go to the nearest emergency department immediately:

• Sudden, severe chest or upper‑back pain that feels “tearing” or “ripping.”
• Sudden, intense abdominal pain, especially if accompanied by a pulsatile mass.
• Signs of shock: rapid heartbeat, fainting, cold clammy skin, or confusion.
• New onset difficulty breathing or unexplained shortness of breath.
• Sudden weakness, numbness, or vision loss suggesting a stroke.
• High fever (>39 °C / 102 °F) with chills in a patient known to have aortic disease.
• Rapidly expanding or painful lump in the abdomen or chest.

Early intervention dramatically improves outcomes for life‑threatening aortic events.

---

**References**

1. Mayo Clinic. “Giant Cell Arteritis.” Accessed 2024. https://www.mayoclinic.org
2. World Health Organization. “Takayasu Arteritis Fact Sheet.” 2023. https://www.who.int
3. CDC. “Infectious Aortitis.” 2022. https://www.cdc.gov
4. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Vasculitis.” 2024. https://www.niams.nih.gov
5. Cleveland Clinic. “Aortitis: Symptoms, Diagnosis, Treatment.” 2023. https://my.clevelandclinic.org
6. Stone JH, et al. “Trial of Tocilizumab in Giant‑Cell Arteritis.” New England Journal of Medicine. 2017;376:1195‑1205.
7. American College of Rheumatology. “2022 Revised Classification Criteria for Giant Cell Arteritis.” 2022.

```